about
The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signalingMelanoma: from melanocyte to genetic alterations and clinical optionsThe ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stabilityGermline ETV6 mutations in familial thrombocytopenia and hematologic malignancyStructural basis for endosomal trafficking of diverse transmembrane cargos by PX-FERM proteinsTunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutationPOT1 loss-of-function variants predispose to familial melanomaThe role of altered nucleotide excision repair and UVB-induced DNA damage in melanomagenesisSignaling Pathways in MelanogenesisResistant mechanisms to BRAF inhibitors in melanomaRecent advances in molecular genetics of melanoma progression: implications for diagnosis and treatmentProtein oxidation, UVA and human DNA repairPolycomb repressive complex's evolutionary conserved function: the role of EZH2 status and cellular backgroundState of the science on prevention and screening to reduce melanoma incidence and mortality: The time is nowStructural Mechanisms and Drug Discovery Prospects of Rho GTPasesMelanocortin 1 Receptor: Structure, Function, and RegulationReview: the Contribution of both Nature and Nurture to Carcinogenesis and Progression in Solid TumoursEpigenetic modulators, modifiers and mediators in cancer aetiology and progressionThe involvement of mutant Rac1 in the formation of invadopodia in cultured melanoma cellsPhytochemicals for the Management of MelanomaRAS-MAPK pathway epigenetic activation in cancer: miRNAs in actionAberrant GLI1 Activation in DNA Damage Response, Carcinogenesis and ChemoresistanceMelanoma: oncogenic drivers and the immune systemTailoring the Treatment of Melanoma: Implications for Personalized MedicineCurrent State of Animal (Mouse) Modeling in Melanoma ResearchThe utility of transposon mutagenesis for cancer studies in the era of genome editing.Cross-species models of human melanomaHistone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune TherapyImmunotherapy of Childhood SarcomasMultiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic TargetsNext-generation sequencing: hype and hope for development of personalized radiation therapy?Mediator kinase module and human tumorigenesisFibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implicationsTargeting melanoma by small molecules: challenges aheadEmerging targeted therapies for melanoma treatment (review)Mutational signatures: the patterns of somatic mutations hidden in cancer genomesApproaches of targeting Rho GTPases in cancer drug discoveryCancer stem cell division: when the rules of asymmetry are brokenFunctional genomics lead to new therapies in follicular lymphoma
P2860
Q21133611-75E22C64-91B4-4D77-8479-0B52892E60C6Q21284811-9FDD1DBC-46AA-4FD9-A0EF-9CEC6F174C00Q24296476-A24469B1-C65C-41DB-A9F5-867272A6198BQ24314163-A23C53CD-C585-4793-8E46-72A1431C0C46Q24314344-13020684-F884-4E16-9B9F-DE9C42667F48Q24315032-37212722-587B-4865-8E56-A5F35D78EEF5Q24320038-D6F46249-A5D4-4A8A-8996-0B2CE738C53EQ24563091-12CEAF6D-7CE1-4400-8A25-63CA5DC8D053Q24626306-0281EB61-1802-4130-912F-B25BFC6673EAQ26739678-352B7E59-A884-4CA2-9AAA-10DDEF957270Q26739717-269215E7-3730-43D9-9111-6AF8962A5E5DQ26740631-9E80FCBC-827B-4728-8D96-7125C09E0E19Q26744266-05FC8206-E981-4D89-AFD1-1F3A86BE3967Q26745416-2F8E7241-EBF7-4456-B767-0569A33A78A8Q26745557-D7D4C1C8-37FC-4CDC-B76F-794C43A5AEB0Q26745863-153D7F1B-4076-4EC0-B027-3EBA8841E063Q26745953-D438176A-286A-4A3C-8FB5-CF2C7A3EFBBAQ26749322-1BF471A1-5C68-469B-AD86-E9D62994DC37Q26766149-98E4B078-D1FF-4E7E-8601-ECBECA18DC0FQ26766212-3D67AA9B-2F78-4958-A6EE-F1BC4784F92CQ26766708-2B706E48-EF21-495D-AFF5-68DE8F26ECD6Q26773479-D2DD4C75-D75A-4560-858D-A95C269CB10AQ26775006-54CFED07-05F7-456D-B3A9-94DEBA3B15C9Q26775598-D90729A0-8437-4C8C-AA02-1D3F0FEC8E93Q26775806-B25EBF45-4C5E-4D5A-AE35-266E519090B4Q26781652-B0D7192A-8F33-4F65-8E68-50CC832376AEQ26781762-08CF41A3-B980-4C88-83BE-7A71AB47944BQ26782090-B8828B7F-3CCF-4B10-88E9-49A3CAF39507Q26783032-F00ECCCB-1C85-4880-86DC-816434EE7F5AQ26795369-D7A3F59C-24D5-4A3E-A2FA-899995ADE7ACQ26795735-024941D6-D908-44A2-9960-8A6F41CE4F1BQ26796485-8C0A8FEB-37D9-4F0D-93F2-C2D29B576CC6Q26800203-339EF925-78D8-49D3-B341-D05A6AABC93DQ26801718-B875C197-E21C-4E8A-B769-AE540D7777E6Q26824642-D5F6CB89-D421-4C89-86E4-8FCF364FCF82Q26829997-C7A6DC7D-4536-4B9D-BD53-96C2E74EBCCCQ26850125-73F5684D-BA84-42E3-8988-C98077777762Q26851300-49498791-C2B5-4B31-B10C-E08AC6EE0A49Q26851679-FD740152-D5EC-42DA-AE98-0B7D14FB2DD8Q26852415-161F1FE0-F4AF-4B59-8718-6CE29D474ECA
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
A landscape of driver mutations in melanoma
@ast
A landscape of driver mutations in melanoma
@en
A landscape of driver mutations in melanoma
@en-gb
A landscape of driver mutations in melanoma
@nl
type
label
A landscape of driver mutations in melanoma
@ast
A landscape of driver mutations in melanoma
@en
A landscape of driver mutations in melanoma
@en-gb
A landscape of driver mutations in melanoma
@nl
prefLabel
A landscape of driver mutations in melanoma
@ast
A landscape of driver mutations in melanoma
@en
A landscape of driver mutations in melanoma
@en-gb
A landscape of driver mutations in melanoma
@nl
P2093
P2860
P50
P3181
P1433
P1476
A landscape of driver mutations in melanoma
@en
P2093
Alex H Ramos
Andrey Sivachenko
Chelsea Place
Daniel Dicara
Dave S B Hoon
Ian R Watson
Jeffrey E Gershenwald
Kelly Chong
P2860
P304
P3181
P356
10.1016/J.CELL.2012.06.024
P407
P50
P577
2012-07-20T00:00:00Z